Infectious Disease In-Vitro Diagnostics Market

The global infectious disease in-vitro diagnostics market size was valued at around USD 60.12 billion in 2022 and is projected to reach USD 83.37 billion by 2031, expanding at a CAGR of around 3.7% during the forecast period, 2023 – 2031. The launch of high-quality and inexpensive medical explications for lab automation along with the wide prevalence of infectious diseases globally are notable factors driving the market growth.

An infectious disease in-vitro diagnostics is primarily designed to detect the main infectious agent in a patient’s body and allow medical practitioners to obtain the right treatment to the patient. The diagnostics involves a range of tests and can help to identify the vectors that cause infectious diseases of patients.

Get Free Sample Report

For instance, the tests also offer crucial information to prevent many potential epidemics such as bacterial infection and help curb the disease spread. Rapid technology advancements facilitate a range of equipment and system that offer high convenience for patients’ self-treatment as it provides improved diagnostic kits to be used for home settings.

The introduction of point of care system and expansion of technology as molecular diagnostics to ensure effective and convenient testing facilities attract the attention of patients for diagnostics.

The outbreak of COVID-19 pandemic has boosted the overall scope for the market expansion and several pharmaceutical companies have started developing several diagnostic kits to detect the virus. Several research and clinical laboratory tests are extensively conducted with massive support from governments across the globe to stop this infectious virus.

In March 2020, the COVID-19 test performed by Abbott got received the attention from the government agencies and was granted for urgent use authorization. In July 2020, the National Institutes of Health (NIH) had invested USD 248.7 million to increase the production of diagnostic test under Rapid Acceleration of Diagnostics initiative to help early detection of the coronavirus and control the spread especially in the US.

Early, the tests are widely applied to the study and research to AIDS and for the detection of the HIV. According to World Health Organization (WHO), more than 37.9 million people were affected by HIV globally and about 1.7 million new cases of HIV were reported in 2018.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing cases of infection diseases among a large number of the aging population worldwide is expected to boost the market growth during the forecast period.

• Growing consumer awareness and rising number of health-conscious people are major drivers that help to rise in the adoption of early diagnostic tests. These factors are projected to fuel the market expansion.

• Advancement in point of care system and availability of advanced but user-friendly diagnostic equipment for the use of home setting environment further push the market growth.

• Less number of skilled lab technicians handling the testing procedures and certain issues regarding the accuracy of test results are major challenges that can hinder the market growth.

• External funding for R&D programs and gradual development of innovative diagnostic technology such as immunoassay and microbiology are expected to offer lucrative opportunities for the market.

Scope of Infectious Disease In-Vitro Diagnostics Market Report

The report on the global infectious disease in-vitro diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Infectious Disease In-Vitro Diagnostics Market Segment Insights

Instruments segment is expected to grow at a rapid pace

Based on products, the global infectious disease in-vitro diagnostics market is divided into instruments, reagents, and services. The instruments segment is further segregated into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others.

The reagents segment is also further classified into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others. The services segment is further partitioned into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others.

The instruments segment held a key share of the market in 2020 and is expected to grow at a rapid pace due to rising demand for diagnostic equipment for testing for various disease treatment applications. However, the reagents segment is anticipated to constitute a large market share during the forecast period owing to the growing use of reagents for various diagnostic development from medical devices manufacturers.

Get Free Sample Report

COVID-19 segment is projected to expand at a considerable CAGR

On the basis of applications, the market is divided into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others. The streptococcus segment is projected to account for a key share of the market.

On the other hand, the COVID-19 segment is anticipated to expand at a considerable CAGR during the forecast period due to increasing technology advancements to enable automated and high-throughput testing for the virus. Extensive research conducted by various institutes in collaboration with pharmaceutical companies to produce a massive quantity of diagnostic kits to meet the global needs, present a key aspect for the segment growth.

Immunoassay segment is expected to expand at a robust growth rate

Based on technology, the global infectious disease in-vitro diagnostics market is divided into immunoassay, molecular diagnostics, microbiology, and others. The immunoassay segment is expected to expand at a robust growth rate in the coming years owing to the need for early treatment of patients and increasing demand for immunoassay methods for the same purpose.

However, the molecular diagnostics segment is anticipated to expand at a rapid CAGR during the forecast period due to large funding for molecular diagnostic research.

Get Free Sample Report

Central laboratories segment is expected to register a high CAGR

On the basis of end users, the market is segmented into point of care, central laboratories, and others. The central laboratories segment is expected to register a high CAGR during the forecast period due to the rapid expansion of clinical laboratory facilities across the globe due to rising demand for numerous testing process.

However, the point of care segment is projected to register healthy growth rate in the coming years owing to wide preference for self-treatment from patients and rising inclination for home setting screening process. Moreover, the presence of these laboratories in emerging and underdeveloped markets is expected to contribute in the development of new solutions to offer prompt PoC results. This is anticipated to further boost the growth of the segment.

North America is anticipated to constitute a key market share

In terms of regions, the global infectious disease in-vitro diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounted for a key share of the market, representing more than 35.7% of the global revenue share in 2020 and is expected to hold a major market share during the forecast period.

The regional market growth is attributed to rising cases of infectious diseases and wide prevalence of COVID-19 cases in the region especially in the US. Since the outbreak of the COVID-19 pandemic, the US has been facing the largest COVID cases and highest number of deaths till the end of mid-2021. Moreover, growing encouragement from governments for the expansion of R&D activities and establishment of advanced diagnostic equipment are boosting the regional market growth.

On the other hand, the market of Asia Pacific is anticipated to expand at a robust CAGR during the forecast period due to the growing number of COVID-19 cases due to the advent of second wave in large economies especially in India. Several research organizations in China have been keenly experimenting numerous clinical tests to improve and expand the existing testing technology to fight against infectious diseases, COVID-19 pandemic in particular.

Get Free Sample Report

Segments

The global infectious disease in-vitro diagnostics market has been segmented on the basis of

Products

• Instruments
  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB & Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others
• Reagents
  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB & Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others
• Services
  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB & Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others

Technology

• Immunoassay
• Molecular Diagnostics
• Microbiology
• Others

Applications

• MRSA
• Streptococcus
• Clostridium Difficile
• VRE
• CRE
• Respiratory Virus
• Candida
• TB & Drug-resistant TB
• Gastro-intestinal Panel Testing
• Chlamydia
• Gonorrhea
• HPV
• HIV
• Hepatitis C
• Hepatitis B
• COVID-19
• Others

End-users

• Point of Care
• Central Laboratories
• Others

Regions                  

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• BD
• bioMérieux SA
• Abbott
• Quidel Corporation
• OraSure Technologies, Inc.
• Hologic, Inc. (Gen Probe)
• Danaher
• QIAGEN
• F. Hoffmann-La Roche, Ltd.
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.

Competitive Landscape

Key players competing in the global infectious disease in-vitro diagnostics market include BD; bioMérieux SA; Abbott; Quidel Corporation; OraSure Technologies, Inc.; Hologic, Inc. (Gen Probe); Danaher; QIAGEN; F. Hoffmann-La Roch, Ltd.; Siemens Healthineers AG; and Bio-Rad Laboratories, Inc.

Some of these key players are widely engaged in various market strategies such as mergers, acquisitions, product tests and development, launching new technology, and capcity expansion. Abbott introduced its technology with CE Mark for DETERMINE HBSAG 2 test for observation and treatment of hepatitis B surface antigen in February 2019.